Sareum's TYK2/JAK1 preclinical development candidate molecule, SDC-1802, demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. In addition, Sareum has generated encouraging evidence to suggest that these molecules can function as cancer immunotherapy by modulating the host’s immune system to block tumour cell proliferation in disease models of certain kidney, colon, skin and pancreatic cancers.
Sareum is progressing SDC-1802 through preclinical development (and pending satisfactory progress) into human clinical trials which could begin in 2021.
Sareum is also advancing SDC-1801 as a distinct dual TYK2/JAK1 inhibitor for the potential treatment of autoimmune diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel disease and lupus. SDC-1802 also has the potential to act as a back-up molecule for these autoimmune indications.
Related Items
Immunotherapeutic effects of the TYK2 inhibitor SAR-20351 in syngeneic tumour models. J Reader, T Mitchell et al, AACR-EORTC-NCI 2019 Abstract C086 Poster PDF
TYK2/JAK1 selected for certain cancers
News Release: Successful Outcome from TYK2 Cancer Study
Cambridge News: Sareum Lands £140K Grant to Develop Molecule that Could Treat Leukaemia
Find out more by getting in touch at 
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
